These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31983428)

  • 1. Interaction between IDH1 WT and calmodulin and its implications for glioblastoma cell growth and migration.
    Kang S; Kwon HN; Kang S; Park S
    Biochem Biophys Res Commun; 2020 Mar; 524(1):224-230. PubMed ID: 31983428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH1
    Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X
    Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
    Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
    Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Metabolomic Analysis of IDH1
    Miyata S; Tominaga K; Sakashita E; Urabe M; Onuki Y; Gomi A; Yamaguchi T; Mieno M; Mizukami H; Kume A; Ozawa K; Watanabe E; Kawai K; Endo H
    Sci Rep; 2019 Jul; 9(1):9787. PubMed ID: 31278288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
    Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells.
    Shen X; Wu S; Zhang J; Li M; Xu F; Wang A; Lei Y; Zhu G
    Mol Med Rep; 2020 Sep; 22(3):1949-1957. PubMed ID: 32705169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model.
    Clausing M; William D; Preussler M; Biedermann J; Grützmann K; Richter S; Buchholz F; Temme A; Schröck E; Klink B
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.
    Karpel-Massler G; Ishida CT; Bianchetti E; Zhang Y; Shu C; Tsujiuchi T; Banu MA; Garcia F; Roth KA; Bruce JN; Canoll P; Siegelin MD
    Nat Commun; 2017 Oct; 8(1):1067. PubMed ID: 29057925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
    Machida Y; Nakagawa M; Matsunaga H; Yamaguchi M; Ogawara Y; Shima Y; Yamagata K; Katsumoto T; Hattori A; Itoh M; Seki T; Nishiya Y; Nakamura K; Suzuki K; Imaoka T; Baba D; Suzuki M; Sampetrean O; Saya H; Ichimura K; Kitabayashi I
    Mol Cancer Ther; 2020 Feb; 19(2):375-383. PubMed ID: 31727689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of R132H mutational IDH1 in human U87 glioblastoma cells affects the SREBP1a pathway and induces cellular proliferation.
    Zhu J; Cui G; Chen M; Xu Q; Wang X; Zhou D; Lv S; Fu L; Wang Z; Zuo J
    J Mol Neurosci; 2013 May; 50(1):165-71. PubMed ID: 23011765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating Mechanisms of IDH1 Regulation through Site-Specific Acetylation Mimics.
    Weeks J; Strom AI; Widjaja V; Alexander S; Pucher DK; Sohl CD
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34065652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
    Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
    PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.
    Dexter JP; Ward PS; Dasgupta T; Hosios AM; Gunawardena J; Vander Heiden MG
    J Biol Chem; 2018 Dec; 293(52):20051-20061. PubMed ID: 30381394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased
    Koyasu S; Shimizu Y; Morinibu A; Saga T; Nakamoto Y; Togashi K; Harada H
    J Neurooncol; 2019 Dec; 145(3):441-447. PubMed ID: 31667733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
    Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
    Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An R132H mutation in isocitrate dehydrogenase 1 enhances p21 expression and inhibits phosphorylation of retinoblastoma protein in glioma cells.
    Miyata S; Urabe M; Gomi A; Nagai M; Yamaguchi T; Tsukahara T; Mizukami H; Kume A; Ozawa K; Watanabe E
    Neurol Med Chir (Tokyo); 2013; 53(10):645-54. PubMed ID: 24077277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
    Avellaneda Matteo D; Wells GA; Luna LA; Grunseth AJ; Zagnitko O; Scott DA; Hoang A; Luthra A; Swairjo MA; Schiffer JM; Sohl CD
    Biochem J; 2018 Oct; 475(20):3221-3238. PubMed ID: 30249606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
    Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
    J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study.
    Paldor I; Drummond KJ; Kaye AH
    J Clin Neurosci; 2016 Dec; 34():117-120. PubMed ID: 27522495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.